Intravenous fish oil blunts the physiological response to endotoxin in healthy subjects

Thomas-Thi Pluess, Daniel Hayoz, Mette M Berger, Luc Tappy, Jean-Pierre Revelly, Burkhard Michaeli, Yvon A Carpentier, René L Chioléro, Thomas-Thi Pluess, Daniel Hayoz, Mette M Berger, Luc Tappy, Jean-Pierre Revelly, Burkhard Michaeli, Yvon A Carpentier, René L Chioléro

Abstract

Objective: To assess the effects of intravenous fish oil fat emulsion on the metabolic alterations induced by lipopolysaccharide (LPS) challenge in healthy volunteers.

Design: Two groups of eight healthy subjects were randomized to receive either two pharmacological doses of intravenous FO fat emulsion or no treatment. The FO group received twice 0.5 g/kg 10% emulsion (Omegaven) 48 and 24h before investigation. LPS (2 ng/kg) was injected as a bolus on the investigation day. Systemic parameters, indirect calorimetry, heart rate variability, and platelet membrane phospholipid composition were measured.

Results: Basal EPA and DHA content in platelet phospholipids was low (0.28% and 2.54%, respectively) and increased significantly after FO to 1.68% and 3.32%. LPS induced reproducible effects in all subjects. Fever was higher in the control [corrected] group than in FO group [corrected] the difference was significant from t (120) until t (360). FO blunted the neuroendocrine response: the rise in plasma norepinephrine was sevenfold lower at t (120) while the ACTH peak was fourfold lower. Tumor necrosis factor alpha was significantly lower between t (360) and t (180) in the FO group.

Conclusions: Two doses of intravenous FO fat emulsion modified the phospholipid composition of platelets in healthy subjects. FO blunted fever and increased the neuroendocrine and the inflammatory responses to LPS.

References

    1. Am J Clin Nutr. 1990 Sep;52(3):548-52
    1. Crit Care Med. 2005 Sep;33(9):1994-2002
    1. Metabolism. 1991 Nov;40(11):1152-9
    1. J Clin Endocrinol Metab. 1993 Nov;77(5):1156-63
    1. J Lipid Res. 2003 Mar;44(3):479-86
    1. Am J Clin Nutr. 1988 Apr;47(4):608-28
    1. Clin Nutr. 2007 Feb;26(1):70-7
    1. Lipids. 1988 Jun;23(6):623-5
    1. Am J Respir Crit Care Med. 2003 May 15;167(10):1321-8
    1. Clin Nutr. 1993 Dec;12(6):321-8
    1. Crit Care Med. 2000 May;28(5):1489-96
    1. Crit Care Med. 2002 Jan;30(1):23-31
    1. Proc Nutr Soc. 2006 Aug;65(3):264-77
    1. Lipids. 2004 Dec;39(12):1147-61
    1. Curr Opin Clin Nutr Metab Care. 2001 Mar;4(2):127-30
    1. Am J Physiol. 1991 Oct;261(4 Pt 1):E457-65
    1. Am J Physiol. 1988 Feb;254(2 Pt 2):H377-83
    1. JPEN J Parenter Enteral Nutr. 1989 Mar-Apr;13(2):136-40
    1. Infect Immun. 1995 May;63(5):2041-6
    1. N Engl J Med. 1989 Feb 2;320(5):265-71
    1. Hypertension. 1988 Aug;12(2):214-22
    1. Diabetes Metab. 2003 Jun;29(3):289-95
    1. Ann N Y Acad Sci. 1995 Dec 29;771:41-54
    1. Crit Care Med. 2006 Apr;34(4):972-9
    1. J Trauma. 1997 Feb;42(2):191-8
    1. J Clin Invest. 1992 Aug;90(2):533-6
    1. Am J Physiol. 1992 May;262(5 Pt 2):H1379-86
    1. N Engl J Med. 1995 May 18;332(20):1351-62
    1. Br J Nutr. 2002 Jan;87 Suppl 1:S89-94
    1. Nestle Nutr Workshop Ser Clin Perform Programme. 2002;7:87-98; discussion 98-102

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する